Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Miconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Fortovia Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Galt Pharmaceuticals® Acquires Oravig® (Miconazole Buccal Tablets 50mg) from Fortovia Therapeutics
Details : Oravig is the first and only muco-adhesive buccal tablet formulation of miconazole approved to treat oropharyngeal candidiasis (OPC), also known as oral thrush, in adult patients in the United States.
Product Name : Oravig
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 16, 2020
Lead Product(s) : Miconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Fortovia Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Orphenadrine,Aspirin,Caffeine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Opioid-free Pain Med Orphengesic Forte by Galt Pharmaceuticals Approved by FDA
Details : U.S. Food and Drug Administration approved the company’s Supplemental Abbreviated New Drug Application for Orphengesic Forte, over two months ahead of the scheduled goal date.
Product Name : Orphengesic Forte
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 16, 2020
Lead Product(s) : Orphenadrine,Aspirin,Caffeine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable